Predictmedix AI Launches Next-Generation Clinical-Trial AI Platform
Predictmedix AI (OTC:PMEDF) has launched its Clinical-Trial AI Platform, an advanced solution targeting the $70 billion clinical trials market. The platform leverages patented technology and data from SmartHealth AI Stations to optimize clinical trial planning and execution.
The platform features an adaptive simulation engine, patient-site optimization, cost modeling, and interactive dashboards. Built on validated data streams from over 500,000 SmartHealth scans with approximately 95% accuracy for vital-sign detection, the system provides real-time analytics and continuous intelligence for pharmaceutical sponsors and CROs.
The company is now preparing to offer private demonstrations and explore paid pilot programs with potential clients in the pharmaceutical industry.
Predictmedix AI (OTC:PMEDF) ha lanciato la sua Clinical-Trial AI Platform, una soluzione avanzata rivolta al mercato dei trial clinici da 70 miliardi di dollari. La piattaforma sfrutta tecnologia brevettata e dati provenienti dalle SmartHealth AI Stations per ottimizzare la pianificazione ed l’esecuzione degli studi clinici. La piattaforma presenta un motore di simulazione adattivo, ottimizzazione dei siti paziente, modellazione dei costi e cruscotti interattivi. Costruita su flussi di dati validati da oltre 500.000 scansioni SmartHealth con circa 95% di accuracy nel rilevare i segni vitali, il sistema offre analisi in tempo reale e intelligenza continua per sponsor farmaceutici e CRO. L’azienda si prepara ora a offrire dimostrazioni private e ad esplorare programmi pilota a pagamento con potenziali clienti del settore farmaceutico.
Predictmedix AI (OTC:PMEDF) ha lanzado su Plataforma de IA para Ensayos Clínicos, una solución avanzada dirigida al mercado de ensayos clínicos de 70 mil millones de dólares. La plataforma aprovecha tecnología patentada y datos de las SmartHealth AI Stations para optimizar la planificación y ejecución de ensayos clínicos. La plataforma cuenta con un motor de simulación adaptativa, optimización en sitio de pacientes, modelado de costos y paneles interactivos. Construida sobre flujos de datos validados de más de 500,000 escaneos SmartHealth con aproximadamente 95% de precisión en la detección de signos vitales, el sistema ofrece analítica en tiempo real e inteligencia continua para patrocinadores farmacéuticos y CROs. La compañía se está preparando para ofrecer demostraciones privadas y explorar programas piloto pagos con posibles clientes en la industria farmacéutica.
Predictmedix AI (OTC:PMEDF)는 임상시험 AI 플랫폼을 출시했으며, 700억 달러 규모의 임상시험 시장을 목표로 하는 첨단 솔루션입니다. 플랫폼은 특허 기술과 SmartHealth AI Stations의 데이터를 활용하여 임상시험 계획 및 실행을 optim화합니다. 플랫폼은 적응형 시뮬레이션 엔진, 환자-현장 최적화, 비용 모델링, 인터랙티브 대시보드를 특징으로 합니다. 50만 건이 넘는 SmartHealth 스캔의 검증된 데이터 스트림을 기반으로 하여 약 95%의 정확도로 활력징후를 탐지하며, 시스템은 제약사 스폰서와 CRO를 위한 실시간 분석과 지속적인 인텔리전스를 제공합니다. 회사는 현재 비공개 시연을 제공하고, 제약 산업의 잠재 고객과 유료 파일럿 프로그램을 검토할 계획입니다.
Predictmedix AI (OTC:PMEDF) a lancé sa Plateforme d’IA pour les essais cliniques, une solution avancée destinée au marché des essais cliniques qui représente 70 milliards de dollars. La plateforme s’appuie sur une technologie brevetée et sur les données des SmartHealth AI Stations pour optimiser la planification et l’exécution des essais cliniques. Elle comprend un moteur de simulation adaptatif, une optimisation des sites patients, une modélisation des coûts et des tableaux de bord interactifs. Basée sur des flux de données validés issus de plus de 500 000 scans SmartHealth avec environ 95 % de précision pour la détection des signes vitaux, le système fournit des analyses en temps réel et une intelligence continue pour les sponsors pharmaceutiques et les CROs. L’entreprise se prépare désormais à offrir des démonstrations privées et à explorer des programmes pilotes payants avec des clients potentiels dans l’industrie pharmaceutique.
Predictmedix AI (OTC:PMEDF) hat seine Clinical-Trial AI Platform gestartet, eine fortschrittliche Lösung, die auf den 70-Milliarden-Dollar-Markt für klinische Studien abzielt. Die Plattform nutzt patentierte Technologie und Daten von SmartHealth AI Stations, um die Planung und Durchführung klinischer Studien zu optimieren. Die Plattform verfügt über eine adaptive Simulations-Engine, Patientenstandort-Optimierung, Kostenmodellierung und interaktive Dashboards. Basierend auf validierten Datenströmen aus über 500.000 SmartHealth-Scans mit ca. 95 % Genauigkeit bei der Erkennung von Vitalzeichen bietet das System Echtzeitanalytik und kontinuierliche Intelligenz für Pharma-Sponsoren und CROs. Das Unternehmen bereitet derzeit private Demonstrationen vor und prüft kostenpflichtige Pilotprogramme mit potenziellen Kunden in der Pharmaindustrie vor.
Predictmedix AI (OTC:PMEDF) أطلقت منصة AIClinical-Trial وهي حل متقدم يستهدف سوق التجارب السريرية البالغ 70 مليار دولار. تستفيد المنصة من التكنولوجيا المحمية ببراءة وت البيانات من SmartHealth AI Stations للتحسين من تخطيط وتنفيذ التجارب السريرية. تتميز المنصة بمحرك محاكاة تكييفي، وتحسين للمواقع الخاصة بالمرضى، ونمذجة التكاليف، ولوحات تحكم تفاعلية. مبنية على تدفقات بيانات مُصدقة من أكثر من 500,000 فحص SmartHealth وبما يقارب 95% دقة في اكتشاف العلامات الحيوية، يوفر النظام تحليلات في الوقت الفعلي وذكاء مستمر لرعاة الأدوية و CROs. الشركات تستعد الآن لتقديم عروض خاصة وتستكشف برامج تجريبية مدفوعة مع عملاء محتملين في صناعة الأدوية.
Predictmedix AI (OTC:PMEDF) 已推出其临床试验 AI 平台，这是一款面向 700亿美元临床试验市场 的高级解决方案。该平台利用专利技术和来自 SmartHealth AI Stations 的数据，以优化临床试验的计划与执行。平台具备一个 自适应仿真引擎、患者现场优化、成本建模和交互式仪表板。基于来自超过 50万 SmartHealth 扫描 的经过验证的数据流，约 95% 的准确率用于生命体征检测，该系统为药物赞助商和 CRO 提供实时分析和持续情报。公司现正准备提供私下演示，并与潜在制药行业客户探讨有偿试点计划。
- Platform targets a large addressable market worth $70 billion by 2027
- Technology validated with 500,000+ SmartHealth scans showing 95% accuracy
- End-to-end automation reduces manual work and potential errors
- Real-time adaptive AI enables continuous intelligence and dynamic adjustments
- Platform still in pre-revenue phase pending pilot programs
- Actual results may vary from the reported 95% accuracy rate
- Success dependent on adoption by pharmaceutical companies and CROs
Adaptive "digital brain" designed to cut risk, cost and timelines in the
Toronto, Ontario--(Newsfile Corp. - October 1, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or the "Company"), an emerging leader in AI-powered health and safety technology, announced the launch of its Clinical-Trial AI Platform, an AI-driven solution intended to help pharmaceutical sponsors and contract research organizations (CROs) model, plan, and adapt clinical trials more efficiently.
A Digital Brain for Clinical Trials
Built on patented technology and the high-fidelity dataset generated by SmartHealth AI Stations, the platform is designed to function as a real-time digital support system for trial planning. It ingests and harmonizes diverse datasets—patients, protocols, sites, historical outcomes, and costs—and can update analyses as new data becomes available.
Key Features
- Adaptive Simulation Engine — Runs "what-if" scenarios and refreshes projections as enrollment and site-performance information is received.
- Patient-Site Optimization — Uses AI to recommend patient-site matching that may improve recruitment and reduce dropouts.
- Cost & ROI Modeling — Proprietary algorithms estimate potential budget impact alongside predicted clinical outcomes.
- Interactive Dashboards — Executive and audit views visualize risk, cost, and patient flow with dynamic heatmaps and Sankey plots.
- Compliance-Integrated AI — Tracks data inputs and simulations to support audit and regulatory processes.
Market Context
Industry analysts estimate the global clinical-trials market could exceed
"Clinical development urgently needs smarter tools," said Dr. Rahul Kushwah, COO of Predictmedix. "Our platform is designed to highlight potential clinical trial challenges early, enabling sponsors to make informed adjustments that can help save time and resources and, ultimately, support faster delivery of new therapies."
Distinctive Capabilities
The platform is built around real-time adaptive AI, with automation applied across data ingestion, simulation, and outcome modeling.
- Continuous Intelligence: Projections adjust as enrollment numbers, site performance, or protocol variables change.
- End-to-End Automation: From raw data to executive dashboards, workflows are automated to reduce manual reconciliation.
- Multi-Trial Orchestration: A single environment can simulate multiple protocols and allocate resources across a development portfolio.
- Cost-Outcome Integration: Financial modeling is embedded directly into clinical predictions for unified decision support.
- Validated Data Streams: The system draws on more than 500,000 SmartHealth scans, which internal and third-party assessments have measured at approximately 95 % accuracy for vital-sign detection; actual results may vary.
Predictmedix is preparing to provide private demonstrations and explore paid pilot programs with pharmaceutical sponsors and CROs as opportunities emerge.
1https://www.grandviewresearch.com/industry-analysis/global-clinical-trials-market
Detailed analysis of the company's direct comparables that are trading on CSE and/or TSXV can be found here : https://predictmedix.com/wp-content/uploads/2025/09/PMED.COMPARATIVEANALYSIS_SEP2025.pdf. Details of the company's recent product validations, pilot programs, and strategic partnerships can be found in earlier press releases available at: https://predictmedix.com/press-releases/.
About Predictmedix AI Inc.
Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company’s Smarthealth AI stations – powered by a proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI’s proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at www.Predictmedix.com or follow us on Twitter, Instagram or LinkedIn.
Contact
Dr. Rahul Kushwah, COO
rahul@predictmedix.com
(647) 889 6916
Caution Regarding Forward-Looking Information:
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.
Disclaimer: The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/268289
FAQ
What is Predictmedix AI's new Clinical-Trial AI Platform?
How accurate is Predictmedix's (PMEDF) SmartHealth scanning technology?
What are the key features of PMEDF's Clinical-Trial AI Platform?
What is the market potential for Predictmedix's clinical trial platform?
When will Predictmedix (PMEDF) begin implementing the Clinical-Trial AI Platform?
